The ReadoutEveryone loves a tax cut, deals on the horizon, & yukking it up with Len and George By Damian Garde , Adam Feuerstein , Rebecca Robbins and Ed Silverman Jan. 8, 2018 Reprints Alex Hogan/STAT The Readout @ JPM for January 8, 2018 About the Authors Reprints Damian Garde National Biotech Reporter Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast. [email protected] @damiangarde Adam Feuerstein Senior Writer, Biotech Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast. [email protected] @adamfeuerstein Rebecca Robbins Health Tech Correspondent Rebecca covers health technology. She is the co-author of the newsletter STAT Health Tech. @rebeccadrobbins Ed Silverman Pharmalot Columnist, Senior Writer Ed Silverman covers the pharmaceutical industry. [email protected] @Pharmalot
The Readout Meghana Keshavan Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
The Readout Damian Garde Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
The Readout Damian Garde Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain
The Readout Damian Garde How Biogen got Aduhelm approved, Sanofi’s future in mRNA, & Celgene’s endless saga
The Readout Meghana Keshavan Aduhelm’s impact on Medicare, a new CRISPR therapy, & a Warp Speed retirement
